Phase IIa clinical trial in which 75 non-ICU hospital inpatients will be randomized 2:1 to 7 days of an oral formulation of cyclosporine, Neoral (2.5mg/kg PO BID) + standard of care (SOC) or no Neoral + SOC. The primary endpoint is disease severity based on the World Health Organization (WHO) COVID Ordinal Outcomes Scale, on day 14. Secondary endpoints include safety and changes in serum inflammatory markers.
1. OBJECTIVES
1.1 Primary Objectives
1.1.1 To assess the effect of a 7-day course of oral cyclosporine Neoral on clinical
outcome using the World Health Organization (WHO) COVID Ordinal Clinical Outcomes Scale,
on day 14.
1.2 Secondary Objectives
1.2.1 To establish the safety of Neoral in this patient population (adverse events).
1.2.2 To determine the effect of Neoral on serum inflammatory markers (CRP, d-dimer,
ferritin, ANC (Absolute Neutrophil Count), absolute lymphocyte count, WBC, PLT (daily
while inpatient and including day 14 and 28 for those discharged).
1.2.3 To determine the effect Neoral on viral SARS-CoV2 PCR positivity from baseline
(day 0 to -2) before receiving Neoral to day 14, and from baseline to day 28.
1.2.4 To determine the effect of Neoral on survival (days 14 and 28).
1.2.5 To determine the effect of Neoral on disease improvement (alive and free of
invasive or non-invasive mechanical ventilation; days 14 and 28).
1.2.6 To determine the effect of Neoral on proportion of those requiring invasive
mechanical ventilation.
1.2.7 To determine the effect of Neoral on incidence of deep vein thrombosis.
1.2.8 To determine the effect of Neoral on proportion of patients discharged on day 28.
1.2.9 To determine the effect of Neoral on time to hospital discharge.
1.2.10 To determine the effect of Neoral on disease resolution (alive and discharged
home without oxygen; days 14 and 28).
2. BACKGROUND
2.1 Study Disease(s)
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus that
causes coronavirus disease 2019 (COVID-19). Since initial detection of the virus, more than
10 million cases of COVID-19 have been confirmed worldwide, and COVID-19 is responsible for
more than 505,500 deaths. The United States has seen over 2.5 million cases of COVID-19 and
126,000 deaths from this disease (as of June, 30, 2020). SARS-CoV-2 is efficiently
transmitted from person-to-person and the World Health Organization (WHO) has declared
coronavirus disease 2019 (COVID-19) to be a pandemic.
COVID-19 primarily spreads through the respiratory tract, by droplets, respiratory
secretions, and direct contact. Current data suggest an incubation period of 1-14 days, in
most cases 3-7 days. The virus is highly transmissible in humans and causes severe problems
especially in the elderly and people with underlying chronic diseases. COVID-19 patients
typically present with specific, similar symptoms, such as fever, malaise, and cough. Most
adults or children infected with SARS-CoV-2 have presented with mild flu-like symptoms, but a
few patients are in critical condition and rapidly develop acute respiratory distress
syndrome (ARDS), respiratory failure, multiple organ failure, and death. The case fatality
rate increases with the severity of illness and can reach up to 49% in critically ill
patients.
Unfortunately, specific and effective therapies for COVID-19 are highly limited. Recent
evidence suggest that administration of the anti-viral agent, Remdesivir, to hospital
inpatients with COVID-19 decreases time to recovery from 15 to 11 days and decreases
mortality at 14 days from 11.9% to 7.1%. A preliminary, unpublished analysis from a large,
multicenter, randomized, open-label trial for hospitalized patients in the United Kingdom
showed that patients who were randomized to receive dexamethasone had a reduced rate of
mortality compared to those who received standard of care. This benefit was observed in
patients with severe COVID-19 and was greatest in those who required mechanical ventilation
at enrollment (RECOVERY Trial). These 2 agents are considered in the standard of care (SOC)
for treating patients with COVID-19. However, additional therapies with larger effect sizes
and that are administered at earlier stages to prevent progression to severe COVID-19 are
critically needed.
2.1.1 IND (Investigational New Drug) Agent(s)
The PI has filed an IND with cross-reference letter from Novartis and has received a Safe to
Proceed determination (IND #152065).The rationale for the proposed starting dose is based on
the standard renal transplantation dose, which has a time-honored profile of safety in this
population.
2.2 Rationale
Severe COVID-19. Initial reports from cases identified between February 12 to March 16 in the
United States (U.S.) show rates of hospitalization for COVID-19 to be 21-31%, intensive care
unit (ICU) admissions to be 5- 12%, and fatality to be 2%-3%. High-risk groups for severe
COVID-19 have been identified as the elderly population and those with underlying
comorbidities such as cardiovascular disease, liver disease, pulmonary disease, renal
disease, and diabetes mellitus.
Severe COVID-19 results from a dysregulated hyperimmune state. Severe symptoms of COVID-19
are associated with a hyperimmune response referred to as a cytokine storm. In one study, all
41 patients with COVID-19 admitted to the hospital demonstrated elevated plasma levels of
cytokines and chemokines compared with healthy volunteers that included IL (Interleukin) -1,
-1R, -7, -8, -9, -10, and basic FGF2, GCSF, GMCSF, IFN-γ, IP10, MCP1, M1P1A, MIP1B, PDGF,
TNF-α, and VEGF. Patients admitted to the ICU had higher levels of IL-2, IL-7, IL-10, GCSF,
IP10, MCP1, MIP1A, and TNF-α than patients who did not require ICU admission. Emerging data
has shown that early rapid SARS-CoV-2 replication causes massive epithelial and endothelial
cell death that initiates a cytokine storm and vascular leakage, causes pyroptosis in
macrophages and lymphocytes, and results in exhaustion of T cells and NK (Natural Killer)
cells.
COVID-19 similarities to hemophagocytic lymphohistiocytosis (HLH). HLH is an
under-recognized, hyperinflammatory syndrome characterized by a fulminant and fatal cytokine
storm and multi-organ failure. In adults, HLH is most commonly triggered by viral infections
and occurs in 3.7% to 4.3% cases of sepsis. Cardinal features include unremitting fever,
cytopenias, and hyperferritinemia. Pulmonary involvement (including ARDS) occurs in ~50% of
patients. Each of these clinical features and a highly overlapping cytokine profile is seen
in severe COVID-19. This demonstrates that the clinical presentation and pathologic
mechanisms of severe COVID-19 is similar to, or is HLH.
Cyclosporine (CSA) suppresses hyperimmune states. Calcineurin inhibitors such as CSA suppress
the phosphatase activity of calcineurin, which results in decreased IL-2 production and IL-2
receptor expression. This interrupts a central pathway of T-cell activation and dampens T
cell responses and their associated cytokine storms. CSA is approved by the FDA for three
indications including 1) prophylaxis of organ rejection in kidney, liver, and heart
transplants, 2) treatment of severe active rheumatoid arthritis, and 3) treatment of adult
severe recalcitrant plaque psoriasis. It is critical to consider whether dampening of T-cell
responses using CSA would curtail the vigor of T-cell hyperactivity in COVID-19 disease and
provide an opportunity for these patients to recover.
CSA for COVID-19. Proposed is the use of the calcineurin inhibitor, CSA, for the treatment of
patients with COVID-19. This is based on: 1) observations that COVID-19 disease is associated
with a hyperimmune response very similar to HLH, for which treatment with CSA is effective
and recommended, 2) COVID-19 is associated with dysregulated macrophage activation similar to
macrophage activation syndrome (MAS) which is also therapeutically suppressed by CSA, and 3)
in vitro studies demonstrating that CSA specifically inhibits the replication of
coronaviruses including SARS-CoV-2 with a high degree of specificity.
CSA specifically inhibits coronavirus replication. Coronaviruses are RNA viruses with large
genomes that enter host cells through binding of its transmembrane spike protein with
angiotensin-converting enzyme 2 (ACE2) receptors expressed by host target cells, which is the
same mechanism utilized by SARS-CoV (i.e., SARS). Cyclophilins appear to play a critical role
in the replication of many viruses including coronaviruses, HIV, and hepatitis C virus.
Although the exact mechanisms are not yet well understood, in vitro studies suggest that the
coronavirus' nonstructural protein (Nsp) and nucleocapsid protein bind to cyclophilins, and
knockdown of cyclophilin expression results in near complete inhibition of coronavirus
replication. These data show that viral protein binding to cyclophilins is an important step
for successful coronavirus replication, and inhibition of this interaction by CSA prevents
viral replication. An important study demonstrated that CSA dominantly inhibited replication
of human coronavirus 229E (HCoV-229E), mouse hepatitis virus (MHV), and SARS, and that
treatment with increasing doses of CSA caused a dose-dependent decrease in SARS-CoV
replication in human cells in vitro without affecting cell viability. The same group
demonstrated that CSA inhibited replication of MERS-CoV without affecting cell viability of
mock-infected cells. An independent group demonstrated that increasing concentrations of CSA
treatment of SARS-CoV-infected human cells resulted in a dose-dependent decrease in viral
replication, and inhibited the replication of other coronaviruses, including human CoV-NL63,
CoV-229E, feline CoV serotypes I and II, porcine transmissible gastroenteritis virus (TGEV),
avian infection bronchitis virus (IBV), and two isolates of SARS-CoV. Taken together it is
proposed a dual mechanism in which (1) calcineurin inhibition by CSA inhibits the
phosphorylation of NFAT-P, thus preventing the production of IL-2 and other proinflammatory
cytokines, and (2) CSA inhibits viral replication of coronaviruses, likely through blockade
of calcineurin, causing the inhibition of cyclophilins required for viral replication. Most
recently, it was demonstrated that CSA is highly specific and effective at inhibiting
SARS-CoV-2 replication in various human cells, via inhibition of Cyclophilin.
Safety of CSA in COVID-19. Since April 2020 mounting evidence from various patient
populations has strongly suggested that CSA can be used safely in patients with COVID-19. It
was recently demonstrated that patients with "Immune Mediated Inflammatory Diseases" (IMID)
on various immunosuppressive drugs related to CSA have a "significantly reduced incidence of
SARS-CoV-2 infection". It was reported no significant increase in the incidence or severity
of COVID-19 disease in patients undergoing CSA therapy for Psoriasis, but rather suggested a
potentially milder disease in these patients. Another study of over 4000 patients in Madrid,
Spain demonstrated "a universal relationship between the use of Cyclosporine A and better
outcomes" in patients with COVID-19 disease. In line with the findings from Spain, Cavagna in
Italy observed that transplant patients with ongoing Calcineurin Inhibitor therapy developed
only mild symptoms of COVID-19 disease and concluded that "Calcineurin inhibitor-based
immunosuppressive regimens appear safe" in COVID-19 disease and should not be discontinued.
These recent clinical outcomes data suggest that the use of CSA in patients with COVID-19 is
safe and potentially effective.
2.3 Correlative Studies Background
Correlative studies in this protocol are included as secondary endpoints and are based on: 1)
serum inflammatory markers used clinically as biomarkers to monitor the severity of COVID-19
(CRP, d-dimer, ferritin, ANC, absolute lymphocyte count, WBC (White Blood Cells), PLT), and
2) SARS-CoV-2 viral load by a clinical PCR (Polymerase Chain Reaction) test.
6. TREATMENT AND/OR IMAGING PLAN
6.1 Agent Administration
Treatment will be administered on an inpatient basis.
Arm A Regimen Description Agent Neoral, Investigational, Generic Acceptable, N=50 Patients
2.5 mg/kg PO BID 7 days
Arm B Regimen Description Agent None*, N= 25 Patients 7 days
*Note: The PI has undertaken thorough discussions with the sponsor and generation of placebo
capsules is not feasible for the timing of this study.
Drug: Cyclosporine
2.5 mg/kg PO BID 7 days
Other Name: Neoral
Other: Standard of Care Treatment
Standard of Care Treatment, N= 25 Patients, 7 days
Inclusion Criteria:
3.1.1 Laboratory-confirmed SARS-CoV-2 infection within the past 10 days.
3.1.2 Patients admitted to non-ICU hospital floors or in an emergency department awaiting
admission to a non-ICU hospital bed.
3.1.3 WHO COVID Scale Score 4 (Oxygen by mask or nasal prongs or WHO COVID Scale Score 5
(non-invasive ventilation or high-flow oxygen).
3.1.4 Age 18 to 90 years old.
3.1.5 ECOG (Eastern Cooperative Oncology Group) performance status ≤2 (see Appendix A).
3.1.6 Patients receiving or who have received standard of care therapy for COVID-19 can be
included. This includes Remdesivir, Dexamethasone (or other steroids), and convalescent
plasma.
3.1.7 Ability to understand and the willingness to sign a written informed consent
document.
Exclusion Criteria:
3.2.1 Allergy and/or hypersensitivity to CSA.
3.2.2 GFR<30 mL/min.
3.2.3 ALT (Alanine transaminase) or AST (Aspartate transaminase) >3X upper limits of
normal.
3.2.4 Resistant hypertension (BP>140/90 mm Hg despite adherence to maximal doses of three
antihypertensive agents).
3.2.5 Active bacterial or mycobacterial infection.
3.2.6 Pregnant and/or nursing patients. 3.2.7 Participation in a COVID-19 therapeutic drug
trial.
3.2.8 Patients who have received or who are receiving anti-viral medications including
hydroxychloroquine will not be excluded.
3.2.9 Patients with psychiatric illness/social situations that would limit compliance with
study requirements.
3.2.10 Total cholesterol is < 100 (increased risk of seizure)
3.2.11 Concomitant dosing with Tacrolimus is a relative contraindication (increases overall
immunosuppression and decrease seizure threshold
3.2.12 Concomitant malignancy is a relative contraindication (Neoral can increase
susceptibility to development of neoplasia)
3.2.13 Inability to swallow oral medication
3.2.14 Treatment with immunomodulators or immunosuppressant drugs, including but not
limited to IL-6 inhibitors, TNF inhibitors, anti-IL-1 agents, and JAK inhibitors.
3.2.15 Investigational Antiviral agents
Baylor College of Medicine
Houston, Texas, United States
Bryan Burt, MD, Principal Investigator
Baylor College of Medicine